
    
      Prostate cancer patients who have received treatment with radiation therapy or surgery, who
      have indicators of high-risk disease will be administered 750mg Metformin Extended Release
      twice per day for a period of 9 months. Metformin is an FDA-approved drug that is prescribed
      to treat high blood sugar levels in patients with Type 2 Diabetes. To track prostate cancer
      response in study participants, investigators will obtain prostate specific antigen (PSA)
      levels every three months for the duration of the trial.
    
  